Summary

Objective: To evaluate the survival outcomes and some related factors of R-GEMOX chemotherapy regimen in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma at K Hospital from 2019 to 2024. Subjects and methods: A cross-sectional descriptive study was conducted on 83 patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with RGEMOX regimen at the Hematologic oncology department, K Hospital from May 2019 to June 2024. Results: The average age was 59.9; the male/female ratio was 1; The overall response rate was 51.8%, of which the complete response rate was 20.5%; partial response was 31.3%; The rate of stable disease was 4.8%; the rate of progression disease was 43.4%; The median progression-free survival of the study was 13 months. The median overall survival of the study was 21 months. Refractory was an independent prognostic factor for PFS (p<0.05) and response after treatment was an independent prognostic factor for progression-free survival and overall survival with p<0.001. Conclusion: R-GEMOX regimen prolongs progression-free survival as well as overall survival and is safe for patients with relapsed/refractory B-cell non-Hodgkin lymphoma without high-dose chemotherapy indications.

.